Dendritic cell based-immunotherapy after adjuvant chemotherapy in resectable PDAC
Clémence Toullec, Head and Neck Medical Oncologist at Cancer Institute Avignon Provence – Sainte Catherine, shared a paper by Freek R. van ‘t Land et al, on LinkedIn:
“Outstanding efficacy of dendritic cell based-immunotherapy after adjuvant chemotherapy completion in resectable PDAC recently published in JCO.
Recurrence free survival rate at 2 years 68% in this phase I/II trial. Remember : 2 years RFS was only 42% in the FOLFIRINOX arm in the PRODIGE24 trial.
The way to go for future trials design.”
Source: Clémence Toullec/LinkedIn
Dendritic Cell–Based Immunotherapy in Patients With Resected Pancreatic Cancer
Authors: Freek R. van ‘t Land, Marcella Willemsen, Koen Bezemer, Sjoerd H. van der Burg, Thierry P.P. van den Bosch, Michail Doukas, Amine Fellah, P. Martijn Kolijn, Anton W. Langerak, Miranda Moskie, Elise van der Oost, Nina E.M. Rozendaal, Sara J. Baart, Joachim G.J.V. Aerts, and Casper H.J. van Eijck
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023